July 23, 2024
Bluebird Bio’s Fertility Support Program for Gene Therapies Rejected by HHS Inspector General
Bluebird Bio, Gene Therapy, Fertility Support, HHS Inspector General, Zynteglo, Skysona, Anti-Kickback Rules
Fierce Biotech Layoff Tracker 2024: Industry-Wide Job Cuts Continue
Biotech Layoffs, 2024, MEI Pharma, Rapt Therapeutics, Industry Cuts
GSK’s Dovato Matches Efficacy of Gilead’s Biktarvy with Less Weight Gain in HIV Trial
GSK, Dovato, Gilead, Biktarvy, HIV, weight gain, Spanish trial, PASO DOBLE, ViiV Healthcare
Agilent Technologies Acquires Biovectra for $925 Million to Enhance Biologics and CRISPR Capabilities
Agilent Technologies, Biovectra, Acquisition, Biologics, CRISPR, Contract Development and Manufacturing Organization (CDMO)
MEI Pharma’s Leadership Shakeup: CEO and Medical Head Step Down Amidst Wind-Down Considerations
MEI Pharma, wind down, CEO, medical head, strategic alternatives
Gan & Lee Pharmaceuticals Unveils Promising Mid-Stage Data for Homegrown Obesity Drug
Gan & Lee Pharmaceuticals, Obesity Drug, Mid-Stage Data, Clinical Trial, Weight Loss, GLP-1
Ionis Advances to Phase 3 Trial for Angelman Syndrome Treatment ION582
Ionis Pharmaceuticals, Angelman syndrome, ION582, Phase 3 trial, antisense oligonucleotides, neurological conditions, rare diseases, Biogen, Ultragenyx Pharmaceutical
RAPT Therapeutics Announces Significant Workforce Reduction Following Clinical Hold on Zelnecirnon Trials
RAPT Therapeutics, zelnecirnon, clinical hold, workforce reduction, FDA, clinical trials, atopic dermatitis, asthma, oncology, CCR4 agonist
Tonix Pharmaceuticals Secures $34 Million Contract with US Defense Department for Antiviral Development
Tonix Pharmaceuticals, US Defense Department, Antiviral Development, $34 Million Contract